Clinical Trials Logo

Clinical Trial Summary

Primary objectives :

- To investigate the safety and the tolerability of ATO by IV infusions to patients with SLE,

- To determine the maximum tolerated dose of ATO.

Secondary objectives :

- Evaluation of the clinical and biological response of the SLE to ATO,

- Time of relapse in case of positive response,

- Determination of the efficacy,

- Pharmacokinetic study of ATO.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01738360
Study type Interventional
Source Nantes University Hospital
Contact
Status Terminated
Phase Phase 2
Start date July 2013
Completion date October 2015

See also
  Status Clinical Trial Phase
Completed NCT03749044 - ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies N/A
Completed NCT03218033 - Use of Social Media to Improve Medication Adherence in Adolescents and Young Adults With Systemic Lupus N/A
Not yet recruiting NCT03752983 - Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE
Recruiting NCT03819777 - Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)
Recruiting NCT04894253 - Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus
Not yet recruiting NCT03164720 - SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis
Completed NCT03762824 - Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease Phase 4
Not yet recruiting NCT06435468 - Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases N/A
Completed NCT03430388 - Yellow Fever Vaccine in Patients With Rheumatic Diseases N/A
Completed NCT04108611 - Immune Adsorption Role in Treatment of Resistant Lupus N/A
Not yet recruiting NCT04256577 - Serum Ceramides Level in Systemic Lupus Erythematosus (SLE) Patients as a Novel Marker for Renal Impairment
Completed NCT03540823 - Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Phase 4